827588-90-9

Basic information

• Product Name: 2-PyridinaMine,5-pyrazinyl
• Synonyms: 2-PyridinaMine,5-pyrazinyl;5-(pyrazin-2-yl)pyridin-2-amine;EOS-60904
• CAS NO: 827588-90-9
• Molecular Formula: C₉H₈N₄
• Molecular Weight: 172.18662
• Mol File: 827588-90-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-PyridinaMine,5-pyrazinyl(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PyridinaMine,5-pyrazinyl(827588-90-9)
• EPA Substance Registry System: 2-PyridinaMine,5-pyrazinyl(827588-90-9)

Safety Data

• Hazardous Substances Data: 827588-90-9(Hazardous Substances Data)

Usage

Uses

Used in Coordination Chemistry:
2-PyridinaMine,5-pyrazinyl is used as a chelating agent for the coordination of metal ions, playing a crucial role in the formation of metal complexes and contributing to various applications in coordination chemistry.
Used in Pharmaceutical and Agricultural Chemical Synthesis:
As a precursor, 2-PyridinaMine,5-pyrazinyl is utilized in the synthesis of various pharmaceuticals and agricultural chemicals, contributing to the development of new drugs and agrochemicals with potential therapeutic and pesticidal properties.
Used in Optoelectronics and Material Science:
2-PyridinaMine,5-pyrazinyl is employed in the development of organic light-emitting diodes (OLEDs) and optoelectronic devices, taking advantage of its fluorescent properties to enhance device performance and efficiency.
Used in Medicinal Chemistry Research:
Due to its potential biological activities and anti-tumor properties, 2-PyridinaMine,5-pyrazinyl is a compound of interest in medicinal chemistry research, with the potential to contribute to the discovery and development of novel therapeutic agents.

Upstream product

• 39856-50-3 5-bromo2-nitropyridine 
• 827614-64-2 2-aminopyridine-5-boronic acid pinacol ester 
• 14508-49-7 2-chloropyrazin 
• 1072-97-5 5-bromo-2-pyridylamine 
• 32111-21-0 2-iodopyrazine 

Downstream Products

• 1243245-28-4 2-(4-(2-(difluoromethyl)pyridin-4-yl)phenyl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide 
• 1243245-31-9 2-(3-cyano-4-(2-fluoropyridin-4-yl)phenyl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide 
• 1243245-36-4 2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide 
• 1243245-82-0 2-(4-bromo-3-(trifluoromethyl)phenyl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide 

Relevant articles and documents

2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof

The invention relates to 2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof. Specifically, the invention discloses the compounds represented by a formula (I) shown in the specification, enantiomers, diastereomers, racemates or a mixture of the compounds, or a pharmaceutically acceptable salt, hydrate and solvate of the compounds, a preparation method of the above materials, and applications of the above materials in preparation of an ASK1 small molecule inhibitor, or medicines for preventing and/or treating diseases related to ASK1, especially liver diseases, lung diseases, cardiovascular diseases, kidney diseases and metabolic diseases.

N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY

This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system

The Wnt signaling pathway is a critical developmental pathway which operates through control of cellular functions such as proliferation and differentiation. Aberrant Wnt signaling has been linked to the formation and metastasis of tumors. Porcupine, a member of the membrane-bound O-acyltransferase family of proteins, is an important component of the Wnt pathway. Porcupine catalyzes the palmitoylation of Wnt proteins, a process needed for their secretion and activity. Here we report a novel series of compounds obtained by a scaffold hybridization strategy from a known porcupine inhibitor class. The leading compound 59 demonstrated subnanomolar inhibition of Wnt signaling in a paracrine cellular assay. Compound 59 also showed excellent chemical, plasma and liver microsomal stabilities. Furthermore, compound 59 exhibited good pharmacokinetic profiles with 30% oral bioavailability in rat. Collectively, these results strongly support further optimization of this novel scaffold to develop better Wnt pathway inhibitors.

Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors

Blockade of aberrant Wnt signaling is an attractive therapeutic approach in multiple cancers. We developed and performed a cellular high-throughput screen for inhibitors of Wnt secretion and pathway activation. A lead structure (GNF-1331) was identified from the screen. Further studies identified the molecular target of GNF-1331 as Porcupine, a membrane bound O-acyl transferase. Structure-activity relationship studies led to the discovery of a novel series of potent and selective Porcupine inhibitors. Compound 19, GNF-6231, demonstrated excellent pathway inhibition and induced robust antitumor efficacy in a mouse MMTV-WNT1 xenograft tumor model.

N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS

This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS

The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.